Evaluating suspected thyroid function disorders using free thyroxine measured together with thyroid-stimulating hormone
For more information see: Thyroid Function Ordering Algorithm
Electrochemiluminescence Immunoassay
Free T4 (Thyroxine)
Free Thyroxine
FT4, Serum
Non-Protein Bound Tetraiodothyronine
T4 Free, Serum
Thyroxine, Free
For more information see: Thyroid Function Ordering Algorithm
Serum
Patient Preparation: For 12 hours before specimen collection do not take multivitamins or dietary supplements containing biotin (vitamin B7), which is commonly found in hair, skin, and nail supplements and multivitamins.
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
0.5 mL
Gross hemolysis | OK |
Gross lipemia | OK |
Gross icterus | OK |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 14 days | |
Frozen | 30 days | ||
Ambient | 72 hours |
Evaluating suspected thyroid function disorders using free thyroxine measured together with thyroid-stimulating hormone
For more information see: Thyroid Function Ordering Algorithm
Free thyroxine (FT4) comprises a small fraction of total thyroxine. FT4 is available to the tissues and is, therefore, the metabolically active fraction.
Elevations in FT4 cause hyperthyroidism, while decreases cause hypothyroidism.
Pediatric
0-5 days: 0.9-2.5 ng/dL
6 days-2 months: 0.9-2.2 ng/dL
3-11 months: 0.9-2.0 ng/dL
1-5 years: 1.0-1.8 ng/dL
6-10 years: 1.0-1.7 ng/dL
11-19 years: 1.0-1.6 ng/dL
Adult (> or =20 years): 0.9-1.7 ng/dL
For SI unit Reference Values, see www.mayocliniclabs.com/order-tests/si-unit-conversion.html
Elevated values suggest hyperthyroidism or exogenous thyroxine.
Decreased values suggest hypothyroidism.
Free thyroxine (FT4) works well to correct total T4 values for thyroxine-binding globulin alterations but may give misleading values when abnormal binding proteins are present or the patient has other major illnesses (euthyroid sick syndrome).
Of 26 commonly used pharmaceuticals tested in vitro, only furosemide caused elevated free thyroxine (FT4) findings at the daily therapeutic dosage level.
The test cannot be used in patients receiving treatment with lipid-lowering agents containing dextrothyroxine (D-T4). If the thyroid function is to be checked in such patients, the therapy should first be discontinued for 4 to 6 weeks to allow the physiological state to become re-established.
Binding protein anomalies seen with familial dysalbuminemic hyperthyroxinemia, for example, may cause values which, while characteristic of the condition, deviate from the expected results.
For assays employing antibodies, the possibility exists for interference by human anti-animal antibodies (ie, heterophile antibodies) in the patient sample. Patients who have been regularly exposed to animals or have received immunotherapy or diagnostic procedures utilizing immunoglobulins or immunoglobulin fragments may produce antibodies, eg, human antimouse antibodies (HAMA) that interfere with immunoassays. This may falsely elevate or falsely decrease the results.
Interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur.
1. Melmed S, Polonsky KS, Larsen PR, Kronenberg H. Williams Textbook of Endocrinology. 12th ed. Saunders Company; 2011:348-414
2. Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023
In the Roche free thyroxine (FT4) assay, the determination of free thyroxine is made with the aid of a specific anti-T4 antibody labeled with a ruthenium complex. After addition of biotinylated T4 and streptavidin-coated microparticles, the still-free binding sites of the labeled antibody become occupied, with formation of an antibody-hapten complex. The entire complex becomes bound to the solid phase via interaction of biotin and streptavidin. The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.(Package insert: Elecsys FT4 II. Roche Diagnostics; V4,12/2019)
Monday through Saturday
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
84439
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
FRT4 | T4 (Thyroxine), Free, S | 83122-2 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
FRT4 | T4 (Thyroxine), Free, S | 83122-2 |